Tobramycin
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Antibiotics |
| Catalog number | BBF-04568 |
| CAS | 32986-56-4 |
| Molecular Weight | 467.51 |
| Molecular Formula | C18H37N5O9 |
| Purity | >98% |
Ordering Information
| Catalog Number | Size | Price | Stock | Quantity |
|---|---|---|---|---|
| BBF-04568 | 1 g | $199 | In stock |
Online Inquiry
Add to cartDescription
Tobramycin is an aminoglycoside antibiotic with an IC50 of 9.7 μM.
Specification
| Related CAS | 49842-07-1 (sulphate) |
| Synonyms | NSC 180514; O-3-Amino-3-deoxy-α-D-glucopyranosyl-(1-6)-O-[2,6-diamino-2,3,6-trideoxy-α-D-ribo-hexopyranosyl-(1-4)]-2-deoxy-D-streptamine; Nebramycin 6; Nebramycin VI; Tobramax; Tobramaxin; Tobrex; 3'-Deoxykanamycin B; Aktob; Deoxykanamycin B; 1-Epitobramycin; Bethkis; Gotabiotic; Distobram; Gernebcin |
| Storage | Store at -20°C |
| IUPAC Name | (2S,3R,4S,5S,6R)-4-amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol |
| Canonical SMILES | C1C(C(C(C(C1N)OC2C(C(C(C(O2)CO)O)N)O)O)OC3C(CC(C(O3)CN)O)N)N |
| InChI | InChI=1S/C18H37N5O9/c19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18/h5-18,24-28H,1-4,19-23H2/t5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m0/s1 |
| InChI Key | NLVFBUXFDBBNBW-PBSUHMDJSA-N |
| Source | Streptomyces tenebrarius |
Properties
| Appearance | White Solid |
| Antibiotic Activity Spectrum | Bacteria |
| Boiling Point | 775.4°C at 760 mmHg |
| Melting Point | 152-175°C |
| Density | 1.52 g/cm3 |
| Solubility | Slightly soluble in Methanol, Water |
Reference Reading
1.Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance.
Walsh CC1, Landersdorfer CB2, McIntosh MP2, Peleg AY3, Hirsch EB4, Kirkpatrick CM1, Bergen PJ5. J Antimicrob Chemother. 2016 Apr 26. pii: dkw115. [Epub ahead of print]
OBJECTIVES: Fosfomycin resistance occurs rapidly with monotherapy. This study systematically investigated bacterial killing and emergence of fosfomycin resistance with fosfomycin combinations against Pseudomonas aeruginosa.
2.Diffusion Retardation by Binding of Tobramycin in an Alginate Biofilm Model.
Cao B1, Christophersen L1, Kolpen M1,2, Jensen PØ1, Sneppen K3, Høiby N1,2, Moser C1, Sams T4. PLoS One. 2016 Apr 21;11(4):e0153616. doi: 10.1371/journal.pone.0153616. eCollection 2016.
Microbial cells embedded in a self-produced extracellular biofilm matrix cause chronic infections, e. g. by Pseudomonas aeruginosa in the lungs of cystic fibrosis patients. The antibiotic killing of bacteria in biofilms is generally known to be reduced by 100-1000 times relative to planktonic bacteria. This makes such infections difficult to treat. We have therefore proposed that biofilms can be regarded as an independent compartment with distinct pharmacokinetics. To elucidate this pharmacokinetics we have measured the penetration of the tobramycin into seaweed alginate beads which serve as a model of the extracellular polysaccharide matrix in P. aeruginosa biofilm. We find that, rather than a normal first order saturation curve, the concentration of tobramycin in the alginate beads follows a power-law as a function of the external concentration. Further, the tobramycin is observed to be uniformly distributed throughout the volume of the alginate bead.
3.Evaluation of a Once-Daily Tobramycin Regimen to Achieve Target Concentrations in Adult Patients with Cystic Fibrosis.
Staubes BA1, Metzger NL2,3, Walker SD4, Peasah SK2. Pharmacotherapy. 2016 May 3. doi: 10.1002/phar.1762. [Epub ahead of print]
STUDY OBJECTIVE: To evaluate the success of an initial tobramycin dosing regimen to achieve target peak and trough concentrations in adult patients with pulmonary exacerbations of cystic fibrosis (CF).
4.Inhalation of tobramycin using simulated cystic fibrosis patient profiles.
Haynes A1, Geller D2, Weers J1, Ament B1, Pavkov R3, Malcolmson R1, Debonnett L3, Mastoridis P3, Yadao A3, Heuerding S4. Pediatr Pulmonol. 2016 May 1. doi: 10.1002/ppul.23451. [Epub ahead of print]
INTRODUCTION: TOBI® Podhaler™ is a capsule-based drug-device combination (tobramycin inhalation powder [TIP] 28 mg capsules via unit-dose dry powder T-326 Inhaler [Podhaler™]) developed for treatment of Pseudomonas aeruginosa infection in cystic fibrosis (CF). We explored how inspiratory flow profiles and mouth-throat geometries affect drug delivery with the T-326 Inhaler.
Recommended Products
| BBF-01693 | Doxorubicin EP Impurity A (Daunorubicin) | Inquiry |
| BBF-03753 | Baicalin | Inquiry |
| BBF-02642 | Lactonamycin | Inquiry |
| BBF-01826 | Deoxymannojirimycin | Inquiry |
| BBF-00764 | Cerebroside C | Inquiry |
| BBF-01829 | Deoxynojirimycin | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
